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Abstract
Prostate cancer (PC) is the second most common cancer in men and the fifth leading
cause of death in men worldwide in 2012 [1]. Oligometastatic disease is defined as the
presence of five or fewer metastatic or recurrent lesions that could be treated by local
therapy to achieve long‐term survival or cure [2]. Androgen deprivation therapy is
currently  the  accepted  treatment  of  metastatic  PC.  However,  the  identification  of
oligometastatic disease in PC with the improvements in diagnostic imaging has lead to
early treatment of these isolated metastases showing some benefit [3]. In this chapter,
we aim to discuss the newer modalities used in the identification of oligometastatic
disease in PC and the advances in treatment.
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1. Introduction
Although oligometastases forms a recent vogue in prostate cancer, the concept of ‘oligometa‐
stases’ was originally described by Hellman and Weichselbaum in 1995 [4]. They theorised that
metastases occurred as a ‘metastatic progression’ from localised disease to widespread systemic
disease [5]. As such, in some patients with limited metastases, they described an ‘oligometa‐
static state’ which occurs as a transitional state between localised and systemic disease [5].
Therefore, rather than classifying all metastatic prostate cancer in to a universal cohort with
poor outcomes, this defined a group of patients who could be identified and treated with
potentially favourable results.
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1.1. Definitions
The nomenclature in ‘oligometastases’ is often used inter changeably and can be sometimes
confusing. The term ‘oligometastasis’ usually refers to metastases (from tumours early in the
chain of progression) limited in number and location because the facility for metastatic growth
has not been fully developed and the site for growth is restricted, while ‘oligometastatic
disease’ is defined as solitary or few detectable metastatic lesions (<5 metastases) that are
usually confined to a single organ [5]. Although sometimes oligometastases can refer to
synchronous or metachronous disease, it should be stressed that the key feature determining
the behaviour of oligometastases is its metastatic potential. As such, ‘true oligometastases’ are
defined as oligometastases with limited metastatic potential, while ‘induced oligometastases’
occur following successful systemic treatment have more extensive malignant capacities and
were spared from eradication by pharmacological means, local immunological conditions or
from the development of resistant clones [6].
In prostate cancer, induced oligometastases can be further divided into those with a rising PSA
following primary therapy who has oligometastases on imaging or those with castrate‐
resistant prostate cancer (CRPC) with a rising PSA level and image‐detected oligometastases
[7].
2. The evidence for treatment of oligometastases
Treatment of liver metastases in colorectal cancer, lung metastases from a variety of cancers
and adrenal metastases in lung cancer have demonstrated in improved survival and in some
cases even cure; forming the basis of treating oligometastases in cancers [6]. Currently,
androgen deprivation therapy is the optimal treatment for widespread metastatic prostate
cancer. Studies have demonstrated that those men on androgen deprivation therapy for ≤3
metastases had much superior outcomes compared to those with larger number of metastases
[8, 9]. A further study demonstrated that men with prostate cancer who developed ≤5 meta‐
static sites had better survival than those with >5 lesions [10]. With the recent shift, the
landscape of prostate cancer diagnostics and treatments has changed significantly offering the
opportunity to accurately identify and treats the oligometastases. Treatment of oligometasta‐
ses in prostate cancer can offer better local cancer control and reduce the systematic metastatic
potential and its complications by reducing seeding of established metastases control of the
overall disease burden and perhaps even cure [7]. In addition, the treatment of oligometastatic
disease in prostate cancer delays the need for androgen deprivation and its associated systemic
side effects.
3. Biology of oligometastases
As described in Paget's ‘seed and soil’ hypothesis, metastases occur due to an interaction
between the tumour cell and the targeted organ, which supports the secondary growth of the
Prostate Cancer - Leading-edge Diagnostic Procedures and Treatments46
primary tumour cells [6, 11]. This is a complex and selective process which promotes tumour
growth by tumour diversity due to the genetic instability of the tumour cells due to the
telomere erosion, mutations in tumour‐suppressor and DNA‐repair genes, and intrinsic
tumour metabolism (aerobic glycolysis) that is toxic to surrounding normal cell and suppres‐
sion of the host immunity [6]. A number of genes contribute to this metastatic process such as
metastasis ‘initiation’ genes; metastasis ‘progression’ genes and metastasis ‘virulence’ genes
by altering cell adhesion, intravasation, survival in the circulation, extravasation, seeding in a
distant site, invasion, and development of the appropriate microenvironment in host organs
and provides a selective advantage of the primary tumour cells to be preserved and amplified
during tumour progression [6]. As such, these primary tumour cells that have limited capa‐
bility in one or more of the necessary biological requirements for metastasis form the basis of
oligometastases [6].
4. Advances in imaging modalities: identification of oligometastases in
prostate cancer
4.1. The conventional modalities: computed tomography (CT) and skeletal scintigraphy
(99MTc‐MDP bone scan)
CT of the abdomen and pelvis forms the main modality of staging patients with intermediate
or high‐risk disease generating valuable information of local advancement, lymph node and
bony involvement of prostate cancer [12] (Figure 1). Studies have demonstrated its specificity
and positive predictive value up to 100%, but its sensitivity remains poor [13]. As such, CT is
gradually being superseded by MRI and the combination PET/CT in recurrent prostate cancer
and oligometastatic disease.
Figure 1. The CT scan of the abdomen and pelvis demonstrates a pelvic lymph node denoted by the white arrow.
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Figure 2. The isotope bone scan demonstrates uptake at the right acetabulum (blue arrow) with several areas of focal
uptake in the axial skeleton, in the ribs and in the left scapula.
99mTc‐methylene diphosphonate (MDP) bone scan is the main imaging modality used to assess
the burden of skeletal disease in patients with PC in intermediate or high‐risk PC or those with
symptoms of bony metastases [12] (Figure 2). However, bone scintigraphy can be non‐specific
and can show increase bone uptake in degenerative joint disease, benign fractures and
inflammation in addition to metastases [14]. However, further functional and anatomical
details can be obtained by integrating the SPECT/CT along with skeletal scintigraphy. While
the negative predictive value of the bone scan is estimated between 87 and 100% in the
literature, its diagnostic yield is highly dependent on the PSA level and clinical stage [12]. As
such bone scans have a poor yield in the early detection of prostate cancer recurrences post‐
definitive treatment.
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4.2. The newer imaging modalities
4.2.1. Multi‐parametric magnetic resonance imaging (MP‐MRI)
MP‐MRI forms an integral role in diagnosis of prostate cancer and localisation for prostatic
biopsy. In addition, it is a very useful tool in determining extra prostatic extension, lymph
nodes or bony metastases in prostate cancer.
A number of studies have demonstrated promising results in detecting local recurrences post‐
radical prostatectomy using MP‐MRI. In patients with biochemical recurrence post‐radical
prostatectomy, MP‐MRI can help determine loco‐regional relapse and small amounts of
healthy residual glandular tissue, scar/fibrosis and granulation tissue, and it may even enable
assessment of the aggressiveness of nodule recurrence by means of ADC values and help
identify tumour deposits and target treatment [15]. One study demonstrated sensitivities and
specificities of 84–88 and 89–100%, respectively in detection of recurrences post‐radical
prostatectomy using MP‐MRI [16].
One of the limitations of MRI is the poor detection of pelvic lymph nodes at PSA levels <0.5 
ng/mL, threshold usually used for salvage therapy. One of the main reasons for this being that
70% of lymph‐node metastases in prostate cancer is <8 mm [17]. In 2008, a meta‐analysis of 24
studies demonstrated that both CT and MRI scans were both poor at detecting pelvic lymph‐
node metastases and there were no differences between the modalities [18]. In fact, they
concluded that reliance on either CT or MRI will misrepresent the patient's true status
regarding nodal metastases, and thus misdirect the therapeutic strategies offered to the patient
[18]. However, there have been significant advances in better anatomical imaging since the
introduction of MP–MRI scans and technology such as lymphotropic nanoparticle–enhanced
MRI can improve the lymph–node detection as well as for biopsy targeting and guidance of
salvage treatment [19].
The increasing use of whole body MP‐MRI may be the future of staging patients with oligo‐
metastatic prostate cancer, as this can also be used to detect bony metastases with good
accuracy [20]. However, this technology is currently mainly limited due to cost and needs
further validation.
4.2.2. Positron emission tomography (PET) scan
Positron emission tomography (PET) scan is a functional scan which commonly uses 18F‐
labeled sodium fluoride (18F‐NaF) and 18F‐labeled 2‐fluoro‐2‐deoxy‐Dglucose (18F‐FDG) as
a radiotracer to detect a metabolic process associated with PC and is fused with a CT to
determine the anatomic location of this process. Despite the role of 18F–FDG PET/CT in
detecting occult metastatic disease in men with biochemical recurrence, and the high detection
rates of osseous metastases with 18F–NaF PET/CT compared to standard imaging [21], they
are still not recommended as first-line imaging modalities due to poor sensitivities in at low
PSA levels and in high-grade tumours [12, 22–24].
A recent meta‐analysis by Evangelista et al. concluded that Choline PET and PET/CT represent
high sensitivity and specificity techniques for the detection of loco‐regional and distant
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metastases in prostate cancer patients with recurrence of disease demonstrating a pooled
sensitivity of 85.6% and a pooled specificity of 92.6% for all sites of disease (prostatic fossa,
lymph nodes and bone) [25]. They further demonstrated a pooled sensitivity of 100% (95% CI
90.5–100%) and pooled specificity of 81.8% (95% CI 48.2–97.7%) for lymph‐node metastases
[25]. In accordance, majority of the studies investigating recurrent oligometastatic prostate
cancer utilised Choline PET as the imaging modality of choice [26].
4.2.3. Prostate specific membrane antigen PET/CT (PSMA PET/CT)
68Ga‐PSMA‐ligand PET/CT utilises the prostate specific membrane antigen which is signifi‐
cantly upregulated in prostate cancer. Although the data for PSMA PET/CT scan in recurrence
of prostate cancer is limited, the early results have been promising. 68Ga‐PSMA–PET improves
detection of lymph nodes, bone or visceral metastases compared with standard imaging
(Figures 3 and 4). One study demonstrated a specificity of 98.9% and sensitivity 65% for
detection of pelvic lymph‐node disease in prostate cancer with PSMA PET, much better than
standard imaging modalities [27]. Furthermore, PSMA–PET–MRI or PSMA–PET–CT enables
a complete staging procedure to be performed by a single examination compared with the
standard staging combination of CT and bone scan.
Figure 3. The PSMA PET scan demonstrates uptake of the tracer in an internal iliac node denoted by the white arrow.
One study using data from 319 patients showed a sensitivity, specificity, negative predictive
value and positive predictive value of PSMA PET/CT of 76.6, 100, 91.4 and 100%, respectively,
in the detection of recurrent prostate cancer [28]. The PSMA detection of recurrent prostate
cancer improved with higher PSA levels and the use of androgen deprivation therapy [28]. A
further study of 248 patients replicated the accuracy of PSMA‐PET with an overall detection
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rate of 89.5% with a mean PSA value of 1.99 ng/ml [29]. As such, PSMA PET/CT is increasingly
being used in studies focussed on oligometastatic disease and may form the cornerstone in
detection and management of oligometastatic disease.
Figure 4. The PSMA PET scan demonstrates uptake of the tracer in a spine at the T9 level denoted by the white arrow.
5. Advances in treatment: treatment of oligometastatic prostate cancer
The conventional treatment of metastatic prostate cancer of androgen deprivation therapy is
associated with a number of systemic side effects most importantly cardiovascular disease,
and a large majority of patients will develop resistance to androgen deprivation. As such,
metastases directed treatment of oligometastatic disease provides opportunity to select and
treat this group of patients, delay the need for androgen deprivation or perhaps even cure.
5.1. Synchronous oligometastatic prostate cancer
5.1.1. Radical prostatectomy
Based on the responses seen by cytoreductive therapy in other cancers such as ovarian, breast
and renal cell carcinoma, a few recent studies have investigated the role of radical prostatec‐
tomy in metastatic prostate cancer. Using the SEER database of 8185 men with stage IV M1
prostate cancer, Culp et al. demonstrated that a reduction in cancer specific mortality in men
undergoing radical prostatectomy or brachytherapy [30]. They demonstrated a 44.8% im‐
provement in 5‐year overall survival and 27.1% improvement disease‐specific survival in this
cohort undergoing radical prostatectomy compared with those who did not have surgery or
radiotherapy [30]. However, there were a few significant limitations in this study including
the use of systemic therapy. A further study by Engel et al. replicated these findings using the
Munich Cancer registry data demonstrating an improved survival in those who underwent a
radical prostatectomy in the presence of lymph‐node metastases [31]. While these results
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appear to be promising, in the absence of prospective randomised controlled study data,
radical prostatectomy for oligometastatic disease should be currently considered experimen‐
tal.
5.2. Recurrent disease: oligometastases after primary curative therapy
5.2.1. Salvage lymph‐node dissection
Salvage lymph‐node dissection in the setting of oligometastatic prostate cancer is limited to a
number of cohort studies, with the largest being 59 patients [32]. Recently, a systematic review
combined the results of these smaller series and reported on the results of 151 patients
undergoing salvage pelvic, retroperitoneal or pelvic and retroperitoneal lymph‐node dissec‐
tion for oligometastatic disease [26]. Majority of the studies performed an open salvage lymph‐
node dissection with a median two positive nodes removed with 49 patients receiving post‐
operative prophylactic nodal irradiation and adjuvant ADT in 54% [26].
In the reported largest series with the longest follow‐up of 59 patients undergoing salvage
lymph‐node dissection for oligometastatic prostate cancer, Suardi et al. reported a 8‐year
biochemical recurrence free survival rate of 23% and an overall 8‐year clinical recurrence free
survival of 38% and cancer specific mortality free survival rate of 81% [32]. They found that
the PSA level at salvage LND, biochemical recurrence and the presence of retroperitoneal
lymph‐node metastases all influenced clinical recurrence post‐operative clinical recurrence
[32]. Jilg et al., in their study of 47 patients undergoing salvage LND, reported a clinical
progression‐free survival of 25.6% and cancer specific survival of 77.7% at 5 years [33]. Notably,
the initial disease recurrence post‐salvage lymph‐node dissection occurred again in lymph
nodes in 47–59% in these studies [26].
A large proportion of patients (55%) undergoing salvage lymph‐node dissection developed
complications with the majority being Clavien grade ≤2 [26]. The most common complications
were lymphorrhoea (13%), fever (17%), ileus (10%), and a lymphocele requiring drainage (8%).
Grade 3a complications were observed in 11% of the patients. Only one case of grade 3b
complication (lymphocele requiring surgical drainage) was reported [26].
The current role of salvage lymph‐node dissection in oligometastatic disease remains experi‐
mental and more robust long‐term data are needed prior to being utilised as an established
treatment modality in this setting.
5.2.2. Stereotactic radiotherapy (SBRT)
SBRT is external beam radiotherapy which is used to deliver a high dose of radiation very
precisely to an extra cranial target within the body, as a single dose or a small number of
fractions, thus reducing the amount of normal tissue irradiated and potentially offering
complete ablation of all tissue in the treated area [34]. Therefore, it is a less invasive alternative
to surgery in treating lymph‐node recurrence and bony metastases in prostate cancer.
Similar to salvage lymph‐node dissection, the evidence is based on small cohort studies. In
one of the larger studies of 50 men with recurrence, post‐definitive therapy for Schick et al.
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demonstrated that a short duration androgen deprivation with and high‐dose irradiation to
the metastatic lesions median follow‐up of 31 months (range 9–89) the 3‐year biochemical
relapse‐free survival, clinical failure‐free survival, and overall survival rates were 54.5, 58.6
and 92%, respectively [35]. In a contrasting large cohort of 50 patients receiving SBRT with a
median follow up of 2 years, Decaestecker et al. reported a 35% progression free survival at
2 years [36]. The differences in progression‐free survival rates are attributed to the use of
adjuvant ADT and prophylactic nodal irradiation used in the study by Schick, offering better
progression‐free survival [31]. A further interesting observation between the studies was the
pattern of first progression where, 75% presented with oligometastases in the series of
Decaestecker et al. compared with only 10% in the series of Schick et al. The recurring patents
then went on to receive second or third course of SBRT in the former study [36]. A short PSA
doubling time before SBRT predicted worse PFS in the study by Decaestecker et al. [36]. A
recent retrospective series of 19 men who had biochemical recurrence post‐local therapy for
prostate cancer with oligometastases (≤3 metachronous metastases) demonstrated a 21 
months’ median distant progression‐free survival with 3‐ and 5‐year DPFS of 31 and 15%,
respectively [37]. Also importantly, this study demonstrated a delay of androgen deprivation
by 28 months [37].
A further study by Tabata et al. demonstrated overall survival rates of up to 90.5% in patients
receiving radiotherapy for oligometastatic disease of the bones with long‐term pain control in
oligometastatic disease and no spinal cord compression or pathological fractures occurring at
the radiated sites [38]. CyberKnife‐based stereotactic ablative radiotherapy is newer modality
being utilised in oligometastatic disease with early studies also demonstrating good local
control and relatively good PSA response [39].
The toxicity rates of SBRT six studies were reviewed in their analysis by Ost et al. [26]. Sixteen
per cent of patients had late complications with the majority being grade 2 toxicity, mainly
gastrointestinal in 8.5%, with one case of grade 3 toxicity (macroscopic haematuria) [26].
6. Conclusion
The concept of oligometastases in prostate cancer offers a newer approach to patients with the
presence of five or fewer metastatic or recurrent lesions that could be treated by local therapy
to achieve long‐term survival or cure. Furthermore, it offers the advantage of delaying the
need for androgen deprivation therapy and its associated side effects. Treatment of oligome‐
tastatic prostate cancer relies on early diagnosis in order to offer the best outcomes for these
patients. Therefore, improvements in prostate cancer diagnostics such as choline PET, whole‐
body multi‐parametric MRI, PSMA PET can provide early identification of this group of
patients, while surgical and targeted radio‐ablative techniques can deliver advanced thera‐
peutics to the targeted regions. While the future management strategies appear promising for
oligometastatic prostate cancer, it currently remains experimental.
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